您当前的位置：
首页 >
文章列表页 >
Comparison of efficacy and safety between tildrakizumab and secukinumab in the treatment of moderate-to-severe plaque psoriasis
更新时间：2026-07-16

    • Comparison of efficacy and safety between tildrakizumab and secukinumab in the treatment of moderate-to-severe plaque psoriasis

    • ZHONGGUO YAOFANG   Vol. 37, Issue 7, Pages: 933-937(2026)

    • DOI：10.6039/j.issn.1001-0408.2026.07.18    

      CLC： R969.4;R758.63

    • Received：26 November 2025，

      Revised：2026-03-13，

      Accepted：13 March 2026，

      Published：15 April 2026

    移动端阅览

  • CHEN Ning,FENG Yaoju,DING Yu.Comparison of efficacy and safety between tildrakizumab and secukinumab in the treatment of moderate-to-severe plaque psoriasis[J].ZHONGGUO YAOFANG,2026,37(07):933-937. DOI： 10.6039/j.issn.1001-0408.2026.07.18.

  •  
  •  

0

Views

106

下载量

0

CSCD

Alert me when the article has been cited
提交
Tools
Download
Export Citation
Share
Add to favorites
Add to my album

Related Articles

Rapid health technology assessment of deucravacitinib in the treatment of moderate-to-severe plaque psoriasis
Efficacy and Safety of Guselkumab in the Treatment of Moderate-to-severe Plaque Psoriasis ：A Systematic Re- view
Posaconazole for prevention of invasive fungal infections： a rapid health technology assessment
Efficacy and safety of letermovir in preventing cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation
低分子肝素钙预防ICU患者静脉血栓栓塞症的临床观察

Related Author

GAO Xing
KONG Shujing
LIU Tianya
QIU Xinran
HAN Jia
LIU Xin
ZHONG Xiaoyan
XU Changjing

Related Institution

Dept. of Pharmacy， the Affiliated Hospital of Xuzhou Medical University
Dept. of Dermatology， the Affiliated Hospital of Xuzhou Medical University
Dept. of Anesthesiology， the Affiliated Hospital of Xuzhou Medical University
Inner Mongolia Autonomous Region Essential Drug Monitoring and Clinical Comprehensive Evaluation Center
School of Pharmacy， Baotou Medical College
0